Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. (FHTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
FHTX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsFoghorn Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.03B, an increase of 36.75% year-over-year from $0.03B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.03B | +$0.01B | +36.75% |
| 2024-12-31 | $0.02B | -$0.01B | -33.83% |
| 2023-12-31 | $0.03B | +$0.01B | +77.63% |
| 2022-12-31 | $0.02B | +$0.02B | +1357.77% |
| 2021-12-31 | $0.00B | +$0.00B | +206.74% |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Foghorn Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Foghorn Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Foghorn Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
FHTX revenue · 4 questionsFHTX's trailing twelve-month (TTM) revenue is $0.03B. That is an increase of 36.75% year-over-year from $0.03B in FY2025.
▸ Source: FMP · Foghorn Therapeutics Inc. SEC filings · GAAP · Foghorn Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026